Beta-blockers should be administered to all patients with heart failure stages II to IV NYHA.
It should also be administered to patients with stage I after myocardial infarction. The low
ejection fraction, especially after myocardial infarction is a strong indication for
beta-blockers, as many studies indicate that administration of these drugs substantially
reduces cardiovascular mortality. Beta-blockers reduce mortality and hospitalizations and
improve the operational phase for all categories of patients with heart failure. Since
beta-blockers, only carvedilol, metoprolol, and recently visoprololi nevimpololi have shown
these benefits and thus, only those have to be administered.
The clinical study Carvedia aims to observe and record the action of beta-blocker carvedilol
on cardiac function in patients with heart failure or reduced left ventricular ejection
fraction after acute myocardial infarction.